Physician profile
William D Gordon
NPI 1528050069
$7,061.10
in general payments reported to CMS, 2019-2025
21 companies · $1,551 in 2025
The $1,551 reported for 2025 was more than what 99% of Sports Vision providers received nationally (typical 2025 total: $83.61).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $841 · 2020: $892 · 2021: $916 · 2022: $892 · 2023: $1,127 · 2024: $842 · 2025: $1,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,442 · Entertainment: $78.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,441.77 |
| Entertainment | $78.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,905.41 | 2019-2025 | Total30, Precision7, Precision 1 |
| Biotissue Holdings INC. | $778.04 | 2022-2025 | |
| Johnson & Johnson Vision Care, INC. | $607.73 | 2019-2025 | Acuvue |
| Optos, INC. | $526.77 | 2019-2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Glaukos Corporation | $472.85 | 2019-2025 | Photrexa Viscous and Photrexa |
| Tarsus Pharmaceuticals, INC. | $389.47 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $338.66 | 2020-2023 | |
| Allergan, INC. | $305.90 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $294.60 | 2024-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $270.75 | 2023-2025 | Cequa |
| Oyster Point Pharma, INC. | $270.51 | 2022-2025 | Tyrvaya, Ryzumvi |
| Coopervision INC. | $196.25 | 2022-2024 | Biofinity Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $163.79 | 2019-2024 | One Series Ultra |
| Alimera Sciences, INC. | $155.71 | 2019-2024 | Yutiq, Iluvien |
| Abbvie INC. | $89.55 | 2022-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $84.06 | 2019 | |
| Bausch & Lomb Americas INC. | $59.47 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Dompe US, INC. | $49.65 | 2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $47.52 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $34.52 | 2025 | Purified Cortrophin Gel |
| Eyevance Pharmaceuticals LLC | $19.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.